These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 25818273)

  • 1. Health technology assessment in Switzerland: a descriptive analysis of "Coverage with Evidence Development" decisions from 1996 to 2013.
    Brügger U; Horisberger B; Ruckstuhl A; Plessow R; Eichler K; Gratwohl A
    BMJ Open; 2015 Mar; 5(3):e007021. PubMed ID: 25818273
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of coverage with evidence development for medical technologies in Switzerland from 1996 to 2012.
    Brügger U; Ruckstuhl A; Horisberger B; Gratwohl A
    Int J Technol Assess Health Care; 2014 Jul; 30(3):253-9. PubMed ID: 25100035
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Coverage with Evidence Development: applications and issues.
    Trueman P; Grainger DL; Downs KE
    Int J Technol Assess Health Care; 2010 Jan; 26(1):79-85. PubMed ID: 20059784
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stakeholders apply the GRADE evidence-to-decision framework to facilitate coverage decisions.
    Dahm P; Oxman AD; Djulbegovic B; Guyatt GH; Murad MH; Amato L; Parmelli E; Davoli M; Morgan RL; Mustafa RA; Sultan S; Falck-Ytter Y; Akl EA; Schünemann HJ
    J Clin Epidemiol; 2017 Jun; 86():129-139. PubMed ID: 28377194
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of technology assessment in health benefits coverage for medical devices.
    Braslow NM; Shatin D; McCarthy DB; Newcomer LN
    Am J Manag Care; 1998 Sep; 4 Spec No():SP139-50. PubMed ID: 10185990
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Health technology assessment in Switzerland.
    Cranovsky R; Schilling J; Faisst K; Koch P; Gutzwiller F; Brunner HH
    Int J Technol Assess Health Care; 2000; 16(2):576-90. PubMed ID: 10932425
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Challenges ahead for federal technology assessment.
    Neumann PJ
    Health Aff (Millwood); 2007; 26(2):w150-2. PubMed ID: 17259197
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Technology coverage decisions by health care plans and considerations by medical directors.
    Steiner CA; Powe NR; Anderson GF; Das A
    Med Care; 1997 May; 35(5):472-89. PubMed ID: 9140336
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Health technology assessment in Switzerland.
    Koch P; Schilling J; Läubli M; Mitscherlich F; Melchart D; Bellucci S
    Int J Technol Assess Health Care; 2009 Jul; 25 Suppl 1():174-7. PubMed ID: 19534839
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Uncertainty and Coverage With Evidence Development: Does Practice Meet Theory?
    Pouwels XGLV; Grutters JPC; Bindels J; Ramaekers BLT; Joore MA
    Value Health; 2019 Jul; 22(7):799-807. PubMed ID: 31277827
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of health technology assessment in coverage decisions on newborn screening.
    Fischer KE; Grosse SD; Rogowski WH
    Int J Technol Assess Health Care; 2011 Oct; 27(4):313-21. PubMed ID: 22004771
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Coverage with evidence development, only in research, risk sharing, or patient access scheme? A framework for coverage decisions.
    Walker S; Sculpher M; Claxton K; Palmer S
    Value Health; 2012 May; 15(3):570-9. PubMed ID: 22583469
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Health technology assessment in Australia: a role for clinical registries?
    Scott AM
    Aust Health Rev; 2017 Mar; 41(1):19-25. PubMed ID: 27028134
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Coverage with evidence development schemes for medical devices in Europe: characteristics and challenges.
    Federici C; Reckers-Droog V; Ciani O; Dams F; Grigore B; Kaló Z; Kovács S; Shatrov K; Brouwer W; Drummond M
    Eur J Health Econ; 2021 Nov; 22(8):1253-1273. PubMed ID: 34117987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EXPANDING EVIDENCE-BASED TECHNOLOGY ASSESSMENT FOR COVERAGE IN WASHINGTON STATE.
    Landaas EJ; Franklin G; Thompson J; Lessler D; Morse J; Mootz R; Hammond SG; Sullivan SD
    Int J Technol Assess Health Care; 2016 Jan; 32(3):140-6. PubMed ID: 27491675
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness and evidence evaluation as criteria for coverage policy.
    Garber AM
    Health Aff (Millwood); 2004; Suppl Web Exclusives():W4-284-96. PubMed ID: 15451997
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transparency vs. closed-door policy: do process characteristics have an impact on the outcomes of coverage decisions? A statistical analysis.
    Fischer KE; Rogowski WH; Leidl R; Stollenwerk B
    Health Policy; 2013 Oct; 112(3):187-96. PubMed ID: 23664301
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Technology assessment: relationship to coverage issues--a case for temporary coverage decisions.
    Diamond LH
    Am J Kidney Dis; 1999 Jan; 33(1):208-10. PubMed ID: 9915294
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insurance coverage for experimental technologies.
    Steinberg EP; Tunis S; Shapiro D
    Health Aff (Millwood); 1995; 14(4):143-58. PubMed ID: 8690340
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Technology assessment, coverage decisions, and conflict: the role of guidelines.
    Sheingold SH
    Am J Manag Care; 1998 Sep; 4 Spec No():SP117-25. PubMed ID: 10185988
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.